Compare XELB & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | NXL |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.5M |
| IPO Year | 2011 | 2022 |
| Metric | XELB | NXL |
|---|---|---|
| Price | $0.36 | $1.87 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.37 | 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | $30.13 | $14.37 |
| Revenue Next Year | $99.55 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.27 | $0.22 |
| 52 Week High | $2.47 | $99.00 |
| Indicator | XELB | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 26.27 | 30.65 |
| Support Level | $0.27 | $0.22 |
| Resistance Level | $1.16 | $5.36 |
| Average True Range (ATR) | 0.09 | 0.43 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.71 | 1.35 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.